Business Wire

Lumen Metabolic Health Device Now Peer-reviewed

17.5.2021 19:57:00 EEST | Business Wire | Press release

Share

Lumen , a health tech company and the creators of the world's first portable metabolism measurement device, has officially been peer-reviewed and published in the Interactive Journal of Medical Research (I-JMR). In collaboration with San Francisco State University, Lumen has validated an ongoing study launched in 2020, which shows the validity of Lumen® to detect changes in metabolic fuel utilization in a comparable manner with a laboratory standard metabolic cart, providing the ability for real-time metabolic information for users under any circumstances.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210517005774/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Lumen now peer-reviewed (Photo: Business Wire)

Developed through years of scientific testing and validation, Lumen is the first handheld, portable device and app that measures your metabolism in real-time with just your breath.

The methodology behind the peer-reviewed validation of Lumen

The study compares the metabolic fuel measurement capabilities of the Lumen device to the gold standard measurement of metabolic carts. These measure the carbon dioxide and oxygen produced from the breath in order to assess metabolic fuel usage (carbohydrates vs. fats). Metabolic carts are known to be costly and only available to the public in laboratory settings.

Lumen has made metabolic testing accessible as the only handheld device available to measure your metabolism from home via the CO2 exhaled from the breath.

"We are thrilled the scientific community recognizes Lumen's ability to measure metabolic fuel utilization as effectively as the metabolic cart. This is groundbreaking because now metabolism measurement is accessible to all from home, rather than relying on solutions that are costly or time-consuming,” says Dr. Shlomo Yeshurun , Head of Research at Lumen.

Results using Lumen and the metabolic cart with young, healthy participants

Participants were young and healthy adults that measured their metabolism at a resting state and in two conditions: fasted and after consuming 150 grams of glucose.

Together with the values obtained from the metabolic cart and data from the Lumen device, changes in metabolic fuel usage were identified.

Both the RER and Lumen CO2 percentage increased significantly after glucose was consumed compared to the fasting state.

Another impactful result indicated that Lumen is in agreement with the gold-standard metabolic cart.

Conclusions

Lumen has the capability to provide accurate information regarding the metabolic state of individuals in agreement with results from the metabolic cart. For the first time, metabolic measurements can be performed from home without the constraints of a laboratory. What was once available only to athletes and medical professionals is now available to all consumers choosing the path to metabolic health.

Lumen plans to continue pioneering metabolic technology, data and knowledge through groundbreaking research and innovative technology to help people achieve optimal health.

The research behind metabolic flexibility

Research (Calcada et al, Gormsen et al) finds that having a flexible metabolism has a profound role in assessing a person's long-term health. People with good metabolic flexibility:

  • Are at lower risk of developing obesity, diabetes and metabolic disorders.
  • Are in a better position to gain muscle and perform better during workouts;
  • Find it easier to lose weight and maintain it

About Lumen

Lumen helps people improve their health and fitness through technology on the forefront of personalized nutrition and metabolism. Conceived and designed by twin sisters, physiology PhDs and Ironman winners, Lumen harnesses the power of our breath to measure metabolism, which is closely linked to weight, fitness and personal health. The Lumen device measures metabolism in a single breath, in less than a minute, which previously was only possible through an hour-long lab test. Available at Lumen.me, Lumen devices ship globally, with the app available on the Apple App Store and Google Play. Lumen is headquartered in Israel, with offices in the United States.

Availability

The Lumen device is available at Lumen.me, currently priced at $299.

The device comes equipped with a travel case, charging dock, USB-C Cable, and Premium Customer Support. Users can download the app for free on the Apple App Store and on Google Play.

For media: images, video and fact sheet can be found in the press kit here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact:
Kyla Blumenfeld, press@lumen.me

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB Launches Digital Marketplace to Scale AI and Digital Innovation Across Energy15.6.2026 15:15:00 EEST | Press release

Global energy technology company SLB (NYSE: SLB) today announced the launch of the SLB Digital Marketplace, a curated digital destination designed to help energy companies rapidly discover and deploy specialized AI agents, domain models, skills, tools, data connectors and digital applications within their existing digital environments. The SLB Digital Marketplace extends the company’s open platform strategy to its Tela™ agentic AI assistant by enabling SLB, partners, independent software vendors (ISVs), developers and customers to bring purpose-built digital capabilities to the energy industry through a single, governed channel. All marketplace offerings are certified against SLB standards for security, interoperability and compatibility before listing. The launch comes as the industry moves toward agentic AI — where software can reason, act and automate across complex technical workflows. As these capabilities proliferate, energy companies will need access to a broader ecosystem of sp

Thales at Eurosatory 2026: Ready today. Ready tomorrow15.6.2026 15:01:00 EEST | Press release

As Eurosatory 2026 opens its doors, Thales is pleased to share with you a complete overview of the announcements that will be made during the first day of this international defense and security show. This document centralises all our news, innovations and partnerships, released on June, 15th, 2026 with direct links to the associated press releases: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615204020/en/ Thales at Eurosatory 2026: Ready today. Ready tomorrow. Thales unveils new AI-powered training data analytics platform to enhance military training.Thales launches next-generation 70mm laser-guided rocket dedicated for counter-drone operations.Thales unveils next-generation Bushmaster Mulga Utility Variant.Thales launches RapidStriker, a complete system for protection against drones.Renault Group and Thales unveil 4 TROOP, an innovative tactical vehicle for future land forces engagements. Thales press releases will b

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery15.6.2026 15:00:00 EEST | Press release

Biocytogen today announced that its Boston research facility has been awarded Full Accreditation by AAALAC International, a globally recognized organization dedicated to promoting excellence in laboratory animal care and use. The accreditation reflects Biocytogen’s continued commitment to maintaining the highest standards of animal welfare, scientific integrity, and operational excellence across its preclinical research and drug discovery activities. Biocytogen’s Boston facility serves as a key hub supporting the company’s expanding portfolio of drug discovery and translational research capabilities. The facility enables a broad range of in vivo studies supporting antibody therapeutics, multispecific antibodies, ADCs, cell therapies, and other innovative biologics programs for pharmaceutical and biotechnology partners worldwide. Through its proprietary BioMice™ platform, Biocytogen has established one of the industry’s most comprehensive collections of genetically engineered disease mo

SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements15.6.2026 13:00:00 EEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Global Market's listing requirements. As noted in the Hearing Panel's May 20, 2026 compliance determination, the Company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027. The Company filed its annual report on Form 20-F for the year ended December 31, 2025 on June 5, 2026. The Notification Letter also stated that the hearing before the Hearings Panel, applied for by the Company, had accordingly been canceled. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission

KRM22 partners with Sigma AI to enhance market surveillance and risk intelligence capabilities15.6.2026 13:00:00 EEST | Press release

KRM22, the technology and software investment company focused on risk management solutions for capital markets, today announced a strategic partnership with Sigma AI, a leading provider of AI-driven financial insights, to integrate advanced news sentiment analytics into its risk management application suite. The integration marks a significant enhancement to KRM22’s capabilities, enabling clients to incorporate real-time market sentiment insights derived from global news sources directly into their risk frameworks. By leveraging Sigma AI’s proprietary natural language processing and machine learning models, KRM22 will help firms better identify emerging risks, anticipate market-moving events, and make more informed trading and compliance decisions. Advancing risk management through AI-driven sentiment analysis As part of the first phase of the collaboration, KRM22 will embed Sigma AI’s news sentiment engine within its application suite. This will provide users with actionable intellige

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye